lotiglipron + dabigatran

**Lotiglipron + dabigatran** is a combination of two drugs studied together to assess pharmacokinetic interactions. Lotiglipron (PF-07081532) is an investigational, orally administered small-molecule glucagon-like peptide 1 receptor agonist designed for overweight and obesity management; it acts by increasing insulin secretion, slowing gastric emptying, and promoting satiety. Dabigatran is an approved oral direct thrombin inhibitor, indicated for reducing risk of stroke and thromboembolism, as well as for treatment and prevention of venous thromboembolism. In clinical research on overweight or obese adults, lotiglipron was shown to reduce plasma dabigatran concentrations by approximately 20% when co-administered; development of lotiglipron has been terminated due to safety concerns, primarily elevation in liver transaminases. No branded combination of these agents is marketed; this combination was studied only in clinical research settings for drug–drug interaction purposes[1][2][3][4].